ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy

Who can take part

• Pathogenic or likely pathogenic mutation in BAG3
• Medical history of diagnosis of DCM
• Stable combination of HF SoC medications
• Adequate acoustic windows for echocardiography
• LVEF > 15% and ≤ 45% at Screening by echocardiography
• Diagnosis of chronic HF for at least 3 months
• NYHA Class I/II/III at Screening

Who cannot take part

• Presence of antibodies to AAV9
• Cardiac ventricular arrhythmia that requires treatment
• History of untreated clinically significant valve disease or a Screening confirmation of severe aortic stenosis, severe mitral stenosis, moderate or severe aortic insufficiency or severe mitral insufficiency
• History of substance abuse that could contribute to cardiac dysfunction; Note: Other inclusion and exclusion criteria may apply
• Presence of a pathogenic or likely pathogenic variant in another gene where that other gene is authoritatively recognized as causal for DCM
• Decompensated HF
• NYHA Class IV